Latest News

Emergency gout admission increase is ‘call to arms’

Publish date: May 30, 2018

 

AT RHEUMATOLOGY 2018

SOURCE: Russel M et al. Rheumatology. 2018;57[Suppl. 3]:key075.186; Whiteman J, et al. Rheumatology. 2018;57[Suppl. 3]:key075.215.

Pages

Recommended Reading

FDA approves once-daily treatment for hyperuricemia in gout
MDedge Rheumatology
Allopurinol extension trial backs treat-to-target approach in gout
MDedge Rheumatology
Febuxostat prevents early gout flares
MDedge Rheumatology
Gout incidence is intertwined with serum urate, but only up to a point
MDedge Rheumatology
FDA: Febuxostat may have increased heart-related death risk
MDedge Rheumatology
Higher water intake linked to less hyperuricemia in gout
MDedge Rheumatology
Rheumatology 911: Inside the rheumatologic emergency
MDedge Rheumatology
Health disparities in rural America: Chronic conditions
MDedge Rheumatology
Febuxostat increases cardiovascular mortality in CARES trial
MDedge Rheumatology
Allopurinol dose not escalated enough to reduce mortality
MDedge Rheumatology

Related Articles